SCHEDULE: Shah Capital Urges Novavax Board to Explore Sale

Activist investor Shah Capital, holding 7.3% of Novavax, demands an immediate strategic review and potential sale of the company, citing persistent underperformance and operational failures.

Summary

• Shah Capital, Novavax's second-largest long-term shareholder, owning 11.8 million shares (7.2%), has formally urged the Board of Directors to undertake a strategic review, including an evaluation of a potential sale of the Issuer.
• The activist investor expressed significant concerns regarding Novavax's share-price underperformance, operational and marketing failures, and recent capital-allocation decisions.
• Shah Capital believes immediate action is necessary to restore investor confidence and realize the full value of the Issuer's assets and technology for shareholders.
• The filing details recent purchases by Shah Capital Opportunity Fund LP, including 284,928 shares at $7.6253 on August 21, 2025, and 71,072 shares at $7.4756 on August 25, 2025.
• As of July 31, 2025, Novavax had 162,421,645 shares of Common Stock outstanding.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative, driven by Shah Capital's strong criticisms of Novavax's persistent underperformance, operational failures, poor capital allocation, and loss of investor confidence. The call for a strategic review and potential sale underscores a deep dissatisfaction with current management and board.

Positives

• Nuvaxovid possesses scientific superiority with better efficacy, tolerability, and durability compared to mRNA competitors, as supported by the Utah Shield study.
• A one-year safety study published in June 2025 demonstrated lower serious adverse events (SAE) for Novavax's vaccine compared to mRNA competition.
• Regulatory tailwinds are favorable for non-mRNA vaccines, with new appointees at HHS/FDA/CDC being critical of mRNA vaccines and several states showing aversion to mRNA solutions.
• Novavax's protein-based technology offers a significant edge for its Combo (Covid/Flu) vaccine program, as it avoids the tolerability issues associated with the large antigen amounts required by mRNA technology for combination vaccines.
• The company held approximately $900 million in cash as of June 30, 2025.

Negatives

• Novavax has experienced persistent share-price underperformance, with the stock down 95% over the past decade, making it one of the worst-performing pharma/biotech stocks.
• Operational and marketing failures include Nuvaxovid rollout slipups in Fall 2023, 2024, and 2025/2026, inadequate 3-month shelf-life for the Fall 2024 season, and critical marketing slips.
• The company achieved a minuscule 2% Covid vaccine market share in the 2024 season despite its product's scientific advantages.
• Recent supply issues for the 2025/2026 Covid rollout resulted in only ~7,000 shots administered by October 2, 2025, compared to ~6 million for mRNA peers.
• Sales have been 'miserable for the third consecutive year,' and Nuvaxovid awareness remains alarmingly low.
• Management's capital-allocation decisions are criticized, specifically an 'extremely expensive' $225 million convertible bond refinance on August 21, 2025.
• The outstanding share count has 'ballooned' since September 2022, earning management the title of 'dilutive king,' compared to a proxy peer average increase of only 14%.
• High short interest of approximately 25% (as of September 15, 2025) significantly exceeds the 9% average for proxy peers, indicating low investor confidence.
• The Board and management are perceived to have lost investor trust and confidence, evidenced by poor proxy approval results and a market value of less than $1.5 billion.

Risks

• Continued significant share-price underperformance and destruction of shareholder value.
• Ongoing operational and marketing failures, including rollout slipups and ineffective marketing, leading to sustained low market share for Nuvaxovid.
• Poor capital-allocation decisions, such as expensive debt refinancings, which could further dilute shareholders or strain financial resources.
• Loss of investor confidence and trust due to perceived lack of accountability and execution failures.
• Inability to capitalize on scientific superiority and regulatory tailwinds for non-mRNA vaccines, allowing competitors to maintain dominance.
• High short interest could continue to exert downward pressure on the stock price.
• Potential for further dilution if aggressive cost-cutting measures are not implemented or if additional capital raises are poorly executed.
• Failure to successfully execute a strategic review or find a suitable buyer, leaving the company vulnerable to continued underperformance.

Future Outlook

Shah Capital believes Novavax's intellectual property and scientific capabilities, particularly its Covid/Flu Combo vaccine, pipeline assets, and Matrix-M adjuvant technology, would have significantly greater upside potential if held by a large, capable pharmaceutical entity. The firm anticipates higher peak sales for Novavax's Flu/Covid Vaccine compared to recent respiratory acquisitions, given the total combined flu/covid sales of $15 billion in 2024 and favorable regulatory tailwinds for non-mRNA solutions globally. Sanofi Q4 2025 milestones and Matrix-M partnerships are also noted as potential positive catalysts.

Management Comments

• Shah Capital expressed concerns regarding the Issuer's significant share-price underperformance, operational and marketing failures, and recent capital-allocation decisions.
• Shah Capital stated their belief that immediate action is needed to restore investor confidence and realize the full value of the Issuer's assets and technology for shareholders.
• Shah Capital finds it unfathomable why Nuvaxovid's market share is once again non-existent given its scientific superiority and positive regulatory tailwinds.
• Shah Capital is at a complete loss for the 'extremely expensive' $225 million convertible bond refinance on August 21, 2025.
• Shah Capital criticized the Board for not implementing aggressive cost-cutting measures earlier, leading to the company earning the title of 'dilutive king.'
• Shah Capital asserts that Novavax's massive underperformance is a direct result of repeated strategic missteps, terrible execution on sales and marketing, and an entrenched Board that has consistently refused to take responsibility for its failed execution.
• Shah Capital recommends an immediate formal strategic review for the sale of the company.

Industry Context

The filing highlights a critical juncture in the vaccine industry, particularly the ongoing competition between mRNA and traditional protein-based vaccine technologies. Shah Capital emphasizes Novavax's scientific superiority in efficacy, tolerability, and durability for its protein-based Nuvaxovid, contrasting it with perceived issues in mRNA vaccines. The increasing regulatory scrutiny and public aversion to mRNA vaccines in several U.S. states create a favorable environment for Novavax's technology. The potential for Novavax's Covid/Flu Combo vaccine is also framed within this context, suggesting it could overcome tolerability challenges faced by mRNA competitors due to its protein-based approach.

Comparison to Industry Standards

• Novavax's share count has 'ballooned' since September 2022, significantly outpacing the proxy peer average increase of only 14%, indicating excessive dilution.
• Novavax's short interest stands at approximately 25% as of September 15, 2025, which is substantially higher than the 9% average for its proxy peers, reflecting a severe lack of investor confidence.
• Nuvaxovid's market share was a 'minuscule 2%' in the 2024 Covid season, despite its 'greater efficacy, tolerability and durability' compared to mRNA competitors, indicating a significant underperformance in commercialization.
• For the 2025/2026 Covid rollout, Novavax administered only ~7,000 shots by October 2, 2025, while mRNA competitors achieved ~6 million shots, demonstrating a profound disparity in rollout effectiveness.
• Novavax's market value of less than $1.5 billion is considered low, especially when compared to a recent $10.5 billion respiratory acquisition with $3 billion peak sales expectations in 2029, suggesting Novavax's assets are undervalued given the $15 billion total combined flu/covid sales in 2024.

Stakeholder Impact

• Shareholders: Potential for significant value creation if a strategic review leads to a sale at a premium, or continued value destruction if current underperformance persists. The current low market value and high dilution are detrimental.
• Employees: A potential sale could lead to changes in management, organizational structure, or workforce, depending on the acquiring entity.
• Customers (patients/healthcare providers): Continued supply issues and low market awareness could limit access to Nuvaxovid, despite its scientific advantages.
• Creditors: The 'expensive' convertible bond refinance could impact the company's financial health and ability to meet future obligations, including ~$400 million in UK/GAVI liabilities.

Next Steps

• The Board of Directors is urged to undertake a formal strategic review, including an evaluation of a potential sale of the Issuer.
• Shah Capital expects immediate action to restore investor confidence and realize the full value of the Issuer's assets and technology.
• The company has potential Sanofi Q4 2025 milestones and Matrix-M partnerships in the works.

Key Dates

Recommendation

While Novavax has faced severe operational and market share challenges, the activist investor's call for an immediate strategic review and potential sale introduces a significant catalyst. The underlying scientific superiority of Nuvaxovid and the potential of its combo vaccine, coupled with favorable regulatory tailwinds for non-mRNA solutions, suggest inherent value that could be unlocked through a sale. However, the current management's execution failures and the high short interest present substantial risks. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the potential for a significant upside if a sale materializes, but also the considerable downside risk if the strategic review fails to yield a favorable outcome or if operational issues persist.

Keywords

Novavax, NVAX, Shah Capital, Activist Investor, Strategic Review, Company Sale, Covid Vaccine, Nuvaxovid, mRNA Vaccines, Protein-based Vaccine, Shareholder Value, Capital Allocation, Biotech, Pharmaceuticals, Vaccine Market Share, Convertible Debt, Dilution, Short Interest, Corporate Governance